Background {#Sec1}
==========

Worldwide, pneumonia remains the leading cause for childhood mortality and adult hospitalization, regardless of progresses in the management and preventive policies \[[@CR1]\]. According to World Health Organization, in 2015 pneumonia causes death for approximately 920,136 children, accounting for 16% of all deaths of children younger than 5 years \[[@CR2]\]. Pneumonia is considered as one of the contributing factors causing burden on health care system \[[@CR3]\].

Pneumonia patients are usually hospitalized due to severe nature of the disease or for the management of comorbid illnesses or associated symptoms. The leading comorbidities of patients with pneumonia include diabetes mellitus, cerebrovascular disease, chronic lung disease, chronic kidney disease, and dementia \[[@CR4]\]. During hospitalization such patients are prescribed with antipyretics, antitussives, antibiotics, and antihistamines \[[@CR5]\]. Apart from the use of aforementioned drugs, such patients are prescribed with a large number of other drugs for the management of associated symptoms and comorbid illnesses \[[@CR6]\]. There is an increased risk of drug-drug interactions (DDIs) with simultaneous use of multiple drugs. DDIs may lead to alteration in the pharmacokinetic parameters or pharmacodynamic profile of drugs \[[@CR7], [@CR8]\]. Many of the negative clinical consequences such as decreased or abolished clinical effectiveness, adverse drug reactions (ADRs), toxicity, hospitalization, and prolonged hospital stay are attributed by DDIs \[[@CR9]\]. DDIs lead to 20--30% of adverse effects, of which 1--2% are life-threatening and 70% need clinical intervention \[[@CR10]\]. Studies have usually addressed the issue of potential DDIs (pDDIs) either in a general way or on the basis of clinical specialties such as geriatrics \[[@CR8]\], internal medicine \[[@CR11]\], oncology \[[@CR12]\], psychiatry \[[@CR13]\], and cardiology \[[@CR14]\]. Despite being one of the most frequent causes of hospitalization \[[@CR15]\], DDIs specifically among hospitalized patients with pneumonia in clinical settings remain unaddressed. Therefore, particular attention is needed in order to conduct studies regarding pDDIs and their clinical relevance among hospitalized patients with pneumonia. Subsequently, such studies will help health care professionals to manage pDDIs and reduce their associated consequences, improve patients' safety, and bring positive clinical outcomes.

Therefore, in this study the prevalence, levels (severity and documentation), predictors (risk factors), and clinical relevance of pDDIs among inpatients diagnosed with pneumonia have been investigated.

Methods {#Sec2}
=======

Study design and settings {#Sec3}
-------------------------

The present study was carried out in internal medicine wards at tertiary care settings (KTH: Khyber Teaching Hospital and HMC: Hayatabad Medical Complex) of the provincial capital (KPK, Khyber Pakhtunkhwa) using a cross-sectional retrospective design. Khyber Teaching Hospital is located at the main university road of the provincial capital, while Hayatabad Medical Complex is located in the Town III of the city. Khyber Teaching Hospital delivers health care and referral services to the residents of Peshawar University Town and adjacent areas, while Hayatabad Medical Complex provides services to the western parts of Peshawar, its neighboring areas, and patients coming from Afghanistan. Both the hospitals are lacking clinical pharmacy services at the level of the wards. Moreover, software-based drug interactions screening programs are lacking in both the hospitals. Patients' data are maintained in the predesigned charts and kept in the main record room of the hospitals.

Inclusion and exclusion criteria {#Sec4}
--------------------------------

The study included inpatients diagnosed with pneumonia during the study period (from 1-Jan-15 to 31-Dec-16), and of either gender and age. Patients' profiles lacking relevant data required for the study were excluded.

Sample size calculation {#Sec5}
-----------------------

The calculated sample size was 383 based on the anticipated prevalence of 52.8% \[[@CR15]\], 95% confidence level, and 5% margin of error \[[@CR16]\]. However, total 431 patients were eligible for inclusion during the study period (from January 2015 to December 2016); therefore, all were included.

Data source {#Sec6}
-----------

Administrative permission was obtained from both the hospitals for the access of patients' clinical record. Convenient sampling technique was used for collecting the following data: patients' demographics, hospital admissions and discharge dates, diagnoses, comorbidities, medications therapy at the hospital, signs/symptoms, and laboratory tests.

Screening for pDDIs {#Sec7}
-------------------

Micromedex Drug-Reax® \[[@CR17]\] was used for checking patients' medications profiles for the identification of DDIs. This software classifies DDIs according to severity- and documentation-levels \[[@CR17]\]. The detail description of these levels is available elsewhere \[[@CR18]--[@CR20]\].

Prevalence of pDDIs as well as prevalence of severity-levels were identified. List of the most frequent (widespread) and clinically important pDDIs was provided. The list also includes potential adverse consequences and levels (severity as well as documentation) of such pDDIs.

Clinical relevance of pDDIs {#Sec8}
---------------------------

Clinical relevance of pDDIs was assessed by evaluating each patient's profile for potential adverse outcomes of top-10 pDDIs. Abnormal patients' signs/symptoms and laboratory tests indicating adverse outcomes of interactions were reported. The clinical features were stratified based on dose differences of interacting drugs. The following cut off points were used for defining higher daily doses, furosemide: ≥60 mg; hydrocortisone: ≥500 mg; aspirin: ≥150 mg; insulin: \> 20 units; isoniazid: ≥150 mg; rifampin: ≥300 mg; calcium containing products: ≥1 g; ceftriaxone: ≥4 g; pyrazinamide: ≥500 mg; ramipril: ≥5 mg; albuterol: ≥15 mg/3 ml; bisoprolol: ≥5 mg. In this study, adverse outcomes were defined as follows, increased blood urea nitrogen (BUN): BUN ≤20 mg/dL; increased serum creatinine: serum creatinine \> 1.06 mg/dL; hypernatremia: serum sodium \> 145 mmol/L; hyponatremia: serum sodium \< 135 mmol/L; hyperkalemia: serum potassium \> 5.5 mmol/L; hypokalemia: serum potassium \< 3.5 mmol/L; hyperchloremia: serum chloride \> 105 mmol/L; hypertension: systolic blood pressure (BP) \> 130 mmHg and/or diastolic BP \> 90 mmHg; hypotension: systolic BP \< 80 mmHg and/or diastolic BP \< 50 mmHg; bradycardia: heart rate \< 70 beats/min; tachycardia: heart rate \> 100 beats/min; increased activated partial thromboplastin time (APTT): APTT \> 35.5 s; increased prothrombin time (PT): PT \> 15.5 s; increased international normalized ratio (INR): INR \> 1.2; decreased platelets: platelets count \< 150,000/μL; hypoglycemia: random blood sugar \< 80 mg/dL or fasting blood sugar \< 70 mg/dL; increased alkaline phosphatase: \> 126 U/L; increased serum bilirubin: \> 1 mg/dL; increased alanine aminotransferase: \> 59 U/L (male), \> 36 U/L (female); leukocytosis: total leukocyte count \> 11,000/μL.

Statistical analysis {#Sec9}
--------------------

Data were presented in frequencies and percentages form and where appropriate median (interquartile range (IQR)) was also provided. Binary logistic regression analysis (both univariate as well as multivariate) with enter method was applied to identify association of various predictors with all interactions as well as major interactions. Presence of drug interactions (overall or major) was taken as dependent variable. Patients characteristics such as gender, age, prescribed medicines, hospitalization, and comorbidities were independent variables in the model. Odds ratios (OR) and 95% confidence intervals (CI) were calculated to identify the strength of association of each independent variable with pDDIs. Multivariate analyses were carried out for variables with a univariate *p*-value of ≤0.15. *P*-value of ≤0.05 was considered statistically significant. All the data were statistically analyzed using SPSS-v23.

Results {#Sec10}
=======

Patients' general characteristics {#Sec11}
---------------------------------

Patients' demographics and comorbidities are shown in Table [1](#Tab1){ref-type="table"}. Of total study subjects, 51% were males. The median number of prescribed drugs was 11 (8--14) and median hospital stay was 4 days (3--6). Majority of the studied patients were aged ≥41 years (85.3%). Most were prescribed with \> 10 drugs (52%). Most frequent hospitalization was ≥3 days (81.7%). Hypertension (*n* = 220), diabetes mellitus (120), stroke (120), and chronic obstructive pulmonary disease (37) were the four leading comorbidities of the studied patients.Table 1General characteristics of study patients (*n* = 431)CharacteristicPatients: n (%^a^)Gender Male220 (51) Female211 (49)Age (years) ≤4063 (14.6) 41--60176 (40.8) \>60192 (44.5) Median (IQR)60 (50--70)Drugs prescribed per patient ≤542 (9.7) 6--10165 (38.3) \>10224 (52) Median (IQR)11 (8--14)Hospital stay (days) ≤279 (18.3) 3--4143 (33.2) \>4209 (48.5) Median (IQR)4 (3--6)Number of comorbidities No comorbidities24 (5.6) 1--2170 (39.4) 3--4127 (29.4) 510 (2.3)Comorbidities Hypertension220 (51) Diabetes mellitus120 (27.8) Stroke120 (27.8) Chronic obstructive pulmonary disease37 (8.6) Ischemic heart disease36 (8.3) Urinary tract infection34 (7.9) Tuberculosis25 (5.8) Hepatitis24 (5.6) Chronic kidney disease20 (4.6) Asthma16 (3.7) Congestive cardiac failure14 (3.2) Post tuberculosis bronchiectasis12 (2.8) Malaria10 (2.3) Decompensated chronic liver disease10 (2.3) Left ventricular failure9 (2.1) Miscellaneous167 (38.7)*IQR* Interquartile range^a^Percentage was calculated out of total number of patients i.e., 431

Prevalence and levels of pDDIs {#Sec12}
------------------------------

Table [2](#Tab2){ref-type="table"} presents prevalence and levels of pDDIs. Of total 431 pneumonia patients, pDDIs were identified in 315 (73.1%) patients. In 22.7% patients, \> 4 pDDIs per patient were found. Based on severity-wise prevalence, 53.8% patients were presented with major-pDDIs, while 51.5% with moderate-pDDIs. Patients with contraindicated- and minor-pDDIs were observed in a low frequency. The total recorded pDDIs were categorized based on the levels of severity and documentation. Total number of pDDIs were 1318, of which 606 were moderate- and 572 were major-pDDIs. According to documentation-levels, 690 were fair- and 491 were good-type.Table 2Prevalence and levels of potential drug-drug interactionsPDDIsPatients: n (%)Prevalence of pDDIs^a^ Overall prevalence of pDDIs315 (73.1)Number of pDDIs per patient 1--2141 (32.7) 3--476 (17.6) \>498 (22.7)Severity-wise prevalence of pDDIs Contraindicated47 (10.9) Major232 (53.8) Moderate222 (51.5) Minor74 (17.1)Levels of pDDIs^b^ Severity-levels  Contraindicated50 (3.8)  Major572 (43.4)  Moderate606 (46)  Minor90 (6.8)Documentation-levels Excellent137 (10.4) Good491 (37.2) Fair690 (52.3)*PDDIs* Potential drug-drug interactions^a^Percentage was calculated out of total number of patients i.e., 431^b^Percentage was calculated out of total number of potential drug-drug interactions i.e., 1318Overall-prevalence is the occurrence of at least one pDDI irrespective of severity type. Total number of pneumonia patients were 431. Therefore, overall-prevalence of pDDIs was 73.1% (315 out of 431)

Risk factors of pDDIs {#Sec13}
---------------------

Results regarding exposure to all types- and major-pDDIs stratified with respect to patient's characteristics are presented in Table [3](#Tab3){ref-type="table"}. PDDIs were more common in males as compared to females. Moreover, pDDIs were more frequently found in patients with an age range of 31 to 60 years, prescribed with \> 10 medicines, and \> 4 days hospitalization. Additionally, concerning comorbidities, pDDIs were mostly reported in hypertension, diabetes mellitus, stroke, and ischemic heart disease.Table 3Exposure to all types- and major-pDDIs stratified with respect to patients' characteristicsPatient's characteristicsAll types of interactionsOnly major interactionsPatients: n (%)Patients: n (%)Gender Male162 (51.4)121 (52.2) Female153 (48.6)111 (47.8)Age (years) ≤3019 (6)13 (5.6) 31--60154 (48.9)116 (50) \>60142 (45.1)103 (44.4)Drugs prescribed per patient ≤57 (2.2)1 (0.4) 6--10103 (32.7)60 (25.9) \>10205 (65.1)171 (73.7)Hospital stay (days) ≤247 (14.9)28 (12.1) 3--497 (30.8)71 (30.6) \>4171 (54.3)133 (57.3)Comorbidities Hypertension173 (54.9)128 (55.2) Diabetes mellitus102 (32.4)77 (33.2) Stroke98 (31.1)75 (32.3) Chronic obstructive pulmonary disease25 (7.9)13 (5.6) Ischemic heart disease30 (9.5)25 (10.8) Urinary tract infection25 (7.9)21 (9.1) Tuberculosis22 (7)21 (9.1) Hepatitis16 (5.1)11 (4.7) Chronic kidney disease16 (5.1)9 (3.9) Asthma14 (4.4)10 (4.3)

Table [4](#Tab4){ref-type="table"} presents ORs with corresponding 95%CIs for pDDIs of all types using univariate model. The results were significant with patient's age 31--60 years (OR = 3.5; *p* \<  0.001) & \> 60 years (OR = 3; *p* = 0.002), prescribed with 6--10 medicines (OR = 8.3; *p* \<  0.001), \> 10 medicines (OR = 53.9; *p* \<  0.001), and \> 4 days hospitalization (OR = 3.1; *p* \<  0.001). Moreover, concerning comorbidities, significant association of all types-pDDIs was found with hypertension (OR = 1.8; *p* = 0.008), diabetes mellitus (OR = 2.6; *p* = 0.001), stroke (OR = 1.9; *p* = 0.01), ischemic heart disease (OR = 1.9; *p* = 0.15), and tuberculosis (OR = 2.8; *p* = 0.09).Table 4Logistic regression analysis based on exposure to all types- and major-pDDIsVariablesAll types-pDDIs^a^Major-pDDIs^b^Univariate analysisMultivariate analysisUnivariate analysisMultivariate analysisOR (95% CI)*p*-valueOR (95% CI)*p*-valueOR (95% CI)*p*-valueOR (95% CI)*p*-valueGender MaleReference--Reference-- Female0.9 (0.6--1.4)0.8----0.9 (0.6--1.3)0.6----Age (Years) ≤30ReferenceReferenceReferenceReference 31--603.5 (1.7--7.2)\<  0.0011.9 (0.7--4.7)0.22.8 (1.3--5.7)0.0062.1 (0.8--5.7)0.1 \>603 (1.5--6)0.0021.5 (0.6--3.9)0.42.3 (1.1--4.8)0.021.7 (0.6--4.5)0.3Drugs prescribed ≤5ReferenceReferenceReferenceReference 6--108.3 (3.5--20)\< 0.0017.3 (2.9--18.4)\<  0.00123.4 (3.1--174.7)0.00226.1 (3.3--210)0.002 \>1053.9 (21--138)\< 0.00143.3 (15.6--120)\<  0.001132.3 (18--985)\<  0.001144 (18--1177)\<  0.001Hospital stay (days) ≤2ReferenceReferenceReferenceReference 3--41.4 (0.8--2.5)0.20.7 (0.3--1.3)0.31.8 (1--3.2)0.040.8 (0.4--1.6)0.5 \>43.1 (1.7--5.4)\< 0.0010.9 (0.5--2)0.93.2 (1.9--5.5)\< 0.0010.9 (0.5--1.9)0.9Comorbidities Hypertension1.8 (1.2--2.8)0.0080.9 (0.5--1.7)0.91.4 (0.9--2.1)0.070.9 (0.5--1.5)0.5 Diabetes mellitus2.6 (1.5--4.5)0.0011.8 (0.9--3.5)0.081.8 (1.2--2.8)0.0081.2 (0.7--2.1)0.5 Stroke1.9 (1.1--3.3)0.011.5 (0.8--2.9)0.191.6 (1.1--2.5)0.031.4 (0.8--2.5)0.2 Chronic obstructive pulmonary disease0.7 (0.4--1.5)0.4----0.4 (0.2--0.9)0.020.4 (0.2--0.9)0.03 Ischemic heart disease1.9 (0.8--4.8)0.151.3 (0.5--3.6)0.62.1 (0.9--4.3)0.051.8 (0.8--4.4)0.2 Urinary tract infection1 (0.5--2.3)0.9----1.4 (0.7--2.9)0.3---- Tuberculosis2.8 (0.8--9.6)0.093.7 (0.9--16.2)0.084.8 (1.6--14.4)0.0048.2 (1.9--34.7)0.004 Hepatitis0.7 (0.3--1.7)0.5----0.7 (0.3--1.6)0.4---- Chronic kidney disease1.5 (0.5--4.6)0.5----0.7 (0.3--1.7)0.4---- Asthma2.7 (0.6--11.8)0.2----1.4 (0.5--4.1)0.5----*pDDIs* Potential drug-drug interactions^a^Hosmer--Lemeshow goodness-of-fit test: *p* = 0.5^b^Hosmer--Lemeshow goodness-of-fit test: *p* = 0.7

In multivariate model, all types of pDDIs were significantly associated with 6--10 prescribed medicines (OR = 7.3; *p* \<  0.001), and \> 10 prescribed medicines (OR = 43.3; *p* \<  0.001) (Table [4](#Tab4){ref-type="table"}).

Table [4](#Tab4){ref-type="table"} further presents logistic regression analysis for exposure to major-pDDIs. The univariate logistic regression analysis showed significant association with patients age 31--60 years (OR = 2.8; *p* = 0.006) & \> 60 years (OR = 2.3; *p* = 0.02), prescribed with 6--10 medicines (OR = 23.4; *p* = 0.002), \> 10 medicines (OR = 132.3; *p* \<  0.001), and hospital stay of 3--4 days (OR = 1.8; *p* = 0.04) & \> 4 days (OR = 3.2; *p* \<  0.001). Moreover, concerning comorbidities, significant association of major-pDDIs was found with hypertension (OR = 1.4; *p* = 0.07), diabetes mellitus (OR = 1.8; *p* = 0.008), stroke (OR = 1.6; *p* = 0.03), ischemic heart disease (OR = 2.1; *p* = 0.05), and tuberculosis (OR = 4.8; *p* = 0.004).

In multivariate model, association of major-pDDIs remained significant with 6--10 prescribed medicines (OR = 26.1; *p* = 0.002), \> 10 prescribed medicines (OR = 144; *p* \<  0.001), and tuberculosis (OR = 8.2; *p* = 0.004) (Table [4](#Tab4){ref-type="table"}).

Widespread interacting drug pairs {#Sec14}
---------------------------------

Most commonly identified and clinically important pDDIs are shown in Table [5](#Tab5){ref-type="table"}. Potential adverse consequences of such interactions were nephrotoxicity, hypokalemia, bleeding, hypoglycemia or hyperglycemia, hepatotoxicity, reduction in therapeutic effectiveness, hypertension, hypotension, gastrointestinal ulceration, QT interval prolongation, and hyperkalemia.Table 5Description of the top-20 and clinically important potential drug--drug interactions in patients with pneumoniaInteracting pairsFrequencySeverityDocumentationPotential adverse outcomesAspirin -- Furosemide40MajorGoodReduced diuretic effectiveness and possible nephrotoxicityFurosemide -- Hydrocortisone39ModerateFairHypokalemiaAspirin -- Clopidogrel37MajorFairIncreased risk of bleedingAspirin -- Insulin33ModerateFairHypoglycemiaIsoniazid -- Rifampin33MajorGoodHepatotoxicityCalcium containing products -- Ceftriaxone33ContraindicatedGoodFormation of ceftriaxone-calcium precipitates and is contraindicated in neonatesPyrazinamide -- Rifampin32MajorGoodHepatotoxicityAspirin -- Ramipril28ModerateFairDecreased ramipril effectivenessAlbuterol -- Furosemide28ModerateFairECG changes or hypokalemiaAspirin -- Bisoprolol23ModerateGoodIncreased blood pressureFurosemide -- Ramipril23ModerateGoodPostural hypotension (first dose)Clarithromycin -- Dexamethasone23MajorFairDecrease clarithromycin exposure and increased dexamethasone exposureAspirin -- Dexamethasone21ModerateGoodIncreased risk of gastrointestinal ulceration and subtherapeutic aspirin serum concentrationsAspirin -- Nitroglycerin20ModerateGoodIncrease in nitroglycerin concentrations and additive platelet function depressionClopidogrel -- Esomeprazole17MajorExcellentReduced plasma concentrations of clopidogrel active metabolite and reduced antiplatelet activityAzithromycin -- Moxifloxacin16MajorFairIncreased risk of QT-interval prolongationAspirin -- Spironolactone16MajorGoodReduced diuretic effectiveness, hyperkalemia, or possible nephrotoxicityClopidogrel -- Omeprazole13MajorExcellentReduced plasma concentrations of clopidogrel active metabolite and reduced antiplatelet activityOmeprazole -- Rifampin13ModerateFairDecreased omeprazole plasma concentrationsRamipril -- Spironolactone13MajorGoodHyperkalemia

Clinical relevance of pDDIs {#Sec15}
---------------------------

Prescribed doses and administration frequencies of the interacting drugs are shown in Table [6](#Tab6){ref-type="table"}. Drugs were given in a variety of the doses and administration frequencies. Following interacting drugs were prescribed with lower doses such as: aspirin, furosemide, clopidogrel, isoniazid, rifampin, pyrazinamide, calcium containing products, ceftriaxone, ramipril, and bisoprolol. While, following drugs were prescribed with higher doses such as: hydrocortisone, insulin, and albuterol. Lower doses of the interacting drugs were more frequent as compared to higher doses.Table 6Prescribed drugs' doses of the top-10 interactionsInteracting pairDose categories^a^Prescribed dose regimenNumber of patientsAspirin + FurosemideLow + Low75 mg OD + 40 mg OD17Low + High75 mg OD + 60 mg OD10Low + Low75 mg OD + 20 mg OD5Low + High75 mg OD + 100 mg OD3Low + High75 mg OD + 40 mg BD2Low + High75 mg OD + 60 mg BD2Low + High75 mg OD + 80 mg OD1Furosemide + HydrocortisoneLow + High40 mg OD + 100 mg QID5High + High80 mg OD + 100 mg QID4Low + Low40 mg OD + 250 mg OD3High + Low60 mg OD + 50 mg QID3High + High60 mg OD + 100 mg QID3Low + High20 mg OD + 100 mg QID3Low + High20 mg OD + 500 mg OD2Low + Low40 mg OD + 50 mg QID2High + Low60 mg OD + 250 mg OD2High + Low40 mg BD + 50 mg BD1Low + High40 mg OD + 250 mg TDS1High + High60 mg OD + 500 mg TDS1High + Low60 mg BD + 100 mg TDS1Low + Low40 mg OD + 100 mg BD1High + Low60 mg OD + 100 mg BD1High + High80 mg BD + 100 mg QID1High + Low60 mg BD + 250 mg OD1High + Low80 mg OD + 250 mg OD1High + High100 mg OD + 100 mg QID1High + High80 mg OD + 500 mg QID1High + Low60 mg BD + 50 mg TDS1Aspirin + ClopidogrelLow + Low75 mg OD + 75 mg OD35High + Low150 mg OD + 75 mg OD1High + Low300 mg OD + 75 mg OD1Aspirin + InsulinLow + High75 mg OD + 20--40 units/day21Low + High75 mg OD + \> 40 units/day6Low + Low75 mg OD + \< 20 units/day5High + Low150 mg OD + 20 units/day1Isoniazid + RifampinLow + Low75 mg OD + 150 mg OD27High + High150 mg OD + 300 mg OD6Calcium containing products + CeftriaxoneLow + Low200 mg/L OD + 2 g OD ATD7Low + High200 mg/L BD + 2 g BD ATD5Low + Low200 mg/L BD + 2 g OD ATD4High + Low1 g OD + 2 g OD ATD4Low + Low200 mg/L OD + 1 g BD ATD3Low + Low200 mg/L TDS + 2 g OD ATD2High + High1 g OD + 2 g BD ATD1Low + Low200 mg/L BD + 1 g BD ATD1Low + Low200 mg/L OD + 1 g OD ATD1Low + Low200 mg/L BD + 1 g OD ATD1Low + High200 mg/L BD + 3 g BD ATD1Low + High200 mg/L OD + 4 g OD ATD1High + High1250 mg BD + 2 g BD ATD1High + Low1250 mg OD + 2 g OD ATD1Pyrazinamide + RifampinLow + Low400 mg OD + 150 mg OD28High + High500 mg OD + 300 mg OD4Aspirin + RamiprilLow + Low75 mg OD + 2.5 mg OD20Low + High75 mg OD + 5 mg OD4Low + High75 mg OD + 10 mg OD3Low + Low75 mg OD + 1.25 mg OD1Albuterol + FurosemideHigh + Low5 mg/ml TDS + 40 mg OD13High + High5 mg/ml TDS + 60 mg OD8High + Low5 mg/ml TDS + 20 mg OD4High + High5 mg/ml TDS + 40 mg BD1Low + Low50mcg/actuation TDS + 40 mg OD1Low + High2 mg OD + 80 mg BD1Aspirin + BisoprololLow + Low75 mg OD + 2.5 mg OD14Low + High75 mg OD + 5 mg OD7High + High300 mg OD + 5 mg OD1High + Low150 mg OD + 2.5 mg OD1*OD* Once a day, *BD* Twice a day, *QID* Four times a day, *TDS* Three times a day, *ATD* Alternate day^a^The following cut off points were used for defining higher daily doses, furosemide: ≥60 mg; hydrocortisone: ≥500 mg; aspirin: ≥150 mg; insulin: \> 20 units; isoniazid: ≥150 mg; rifampin: ≥300 mg; calcium containing products: ≥1 g; ceftriaxone: ≥4 g; pyrazinamide: ≥500 mg; ramipril: ≥5 mg; albuterol: ≥15 mg/3 ml; bisoprolol: ≥5 mg

Table [7](#Tab7){ref-type="table"} shows pertinent clinical features (signs/symptoms and laboratory tests) in lower and higher doses groups for top-10 pDDIs. Clinical manifestations suggesting low drug's efficacy and electrolytes abnormalities were found in patients with the interactions; aspirin + furosemide, calcium containing products + ceftriaxone, and aspirin + ramipril. These features were highly reported among patients with higher doses of furosemide, ceftriaxone, and ramipril. In patients with the interactions furosemide + hydrocortisone and albuterol + furosemide; signs/symptoms of hypokalemia such as tachycardia, constipation, confusion, irregular heart rate, nausea, and vomiting were observed. The signs/symptoms of hypokalemia were highly prevalent among low dose groups of furosemide + hydrocortisone, and high dose groups of furosemide + albuterol. Signs/symptoms and abnormalities in labs suggesting bleeding were found in patients with the interaction, aspirin + clopidogrel. Such patients were prescribed more frequently with low doses of both clopidogrel and aspirin. Signs/symptoms and abnormalities in labs indicating hypoglycemia were more prevalent in patients with the interaction aspirin + insulin and prescribed with high doses of the insulin. Moreover, signs/symptoms and abnormalities in labs suggesting hepatotoxicity were more prevalent among patients with the interactions; isoniazid + rifampin, pyrazinamide + rifampin, and prescribed with high doses of these interacting drugs. Additionally, signs/symptoms of HTN were more frequently reported among high dose groups of aspirin + bisoprolol. Monitoring/management guidelines for top-10 pDDIs are also provided in Table [7](#Tab7){ref-type="table"} \[[@CR17], [@CR21]\].Table 7Clinical relevance, dose considerations, and monitoring/management guidelines of top-10 pDDIs in patients with pneumoniaInteractions^a^Dose categories^a^Signs and symptoms and Laboratory abnormalities^b^Patients: n (%^c^)Monitoring/management guidelinesAspirin -- Furosemide (40)Low + Low (21)Increased BUN14 (66.7)Monitoring of aspirin toxicity and renal function. Response of diuretic should be checked mainly anti-hypertensive effects. High doses are generally not recommended. Alternative may be considered where possible.Increased serum creatinine10 (47.6)Hyponatremia7 (33.3)Hypertension6 (28.6)Dyspnea6 (28.6)Confusion5 (23.8)Drowsiness4 (19)Edema2 (9.5)Hypokalemia2 (9.5)Hyperchloremia1 (4.8)Orthopnea1 (4.8)Chest pain1 (4.8)Nausea1 (4.8)Coma1 (4.8)Low + High (19)Increased BUN16 (84.2)Hypertension13 (68.4)Increased serum creatinine11 (57.9)Dyspnea7 (36.8)Hyperchloremia6 (31.6)Chest pain5 (26.3)Orthopnea5 (26.3)Edema5 (26.3)Confusion4 (21)Hypokalemia4 (21)Hyponatremia4 (21)Drowsiness2 (10.5)Hypernatremia1 (5.3)Hyperkalemia1 (5.3)Nausea1 (5.3)Furosemide -- Hydrocortisone (39)High + High (11)Fever7 (63.6)Serum potassium level and cardiovascular status should be monitored, especially if co-administered. Patients should be advised to inform their physician if they experience potential signs/symptoms of hypokalemia such as constipation, numbness, myalgia, abdominal pain, fatigue, tingling, weakness, irregular heartbeat, muscle cramps, and palpitation.Tachycardia5 (45.4)Constipation5 (45.4)Confusion4 (36.4)Irregular heart rate3 (27.3)Hypokalemia2 (18.2)Vomiting1 (9.1)High + Low (11)Fever5 (45.4)Confusion4 (36.4)Constipation3 (27.3)Hypokalemia3 (27.3)Tachycardia2 (18.2)Irregular heart rate1 (9.1)Low + High (11)Fever7 (63.6)Tachycardia4 (36.4)Constipation3 (27.3)Hypokalemia3 (27.3)Irregular heart rate3 (27.3)Nausea2 (18.2)Confusion1 (9.1)Low + Low (6)Fever4 (66.7)Tachycardia4 (66.7)Hypokalemia3 (50)Irregular heart rate2 (33.3)Vomiting1 (16.7)Aspirin -- Clopidogrel (37)High + Low (2)Bradycardia1 (50)Monitor patients' platelets counts and any sign of bleeding. If an adverse effect is noted, the following options may be considered: (a) Decrease the dose of aspirin (b) GIT protection through proton pump inhibitors and patient should be educated about non-prescribed use of analgesics.Hypotension1 (50)Low + Low (35)Hypotension14 (40)Tachycardia9 (26)Increased APTT9 (26)Drowsiness7 (20)Increased PT7 (20)Weakness6 (17.1)Increased INR5 (14.3)Decreased platelets4 (11.4)Palpitations1 (2.9)Bradycardia1 (2.9)Aspirin -- Insulin (33)Low + High (27)Tachycardia11 (41)Monitoring of patient's blood glucose and clinical signs of hypoglycemia is suggested. Adjust the dose of insulin if necessary.Loss of consciousness7 (26)Drowsiness5 (18.5)Pale3 (11.1)Confusion2 (7.4)Decreased FBS2 (7.4)Irritability1 (3.7)Seizures1 (3.7)Palpitations1 (3.7)Low + Low (5)Pale1 (20)Tachycardia1 (20)High + Low (1)Confusion1 (100)Isoniazid -- Rifampin (33)Low + Low (27)Fever22 (81.5)Monitoring of hepatotoxicity (jaundice, vomiting, fever, anorexia, and LFTs) is advised.Anorexia12 (44.4)Increased ALP9 (33.3)Vomiting6 (22.2)Pale5 (18.5)Anemia3 (11.1)Weight loss2 (7.4)Weakness2 (7.4)Increased ALT2 (7.4)Increased serum bilirubin2 (7.4)Epigastric pain1 (3.7)Hepatic encephalopathy1 (3.7)Tiredness1 (3.7)High + High (6)Fever6 (100)Increased ALP3 (50)AnorexiaEpigastric pain2 (33.3)1 (16.7)Weight loss1 (16.7)Pale1 (16.7)Increased ALT1 (16.7)Increased serum bilirubin1 (16.7)Calcium containing products -- Ceftriaxone (33)Low + Low (19)Fever11 (57.9)Ceftriaxone should not be mixed or administered concomitantly with calcium-containing intravenous preparations in the same intravenous administration line. Monitor patient for signs of nephrotoxicity or decreased ceftriaxone effectiveness.Increased BUN10 (52.6)Cough9 (47.4)Increased serum bilirubin7 (36.8)Leukocytosis7 (36.8)Chest pain2 (10.5)Low + High (7)Cough4 (57.1)Fever3 (42.8)Increased BUN3 (42.8)Increased serum bilirubin3 (42.8)Leukocytosis2 (28.6)Chest pain1 (14.3)High + Low (5)Fever4 (80)Increased BUN2 (40)Increased serum bilirubin2 (40)Leukocytosis2 (40)Chest pain2 (40)Cough1 (20)Sepsis1 (20)High + High (2)Increased BUN2 (100)Increased serum bilirubin2 (100)Leukocytosis2 (100)Pyrazinamide -- Rifampin (32)Low + Low (28)Fever23 (82.1)Monitoring of LFTs during treatment is recommended.Anorexia13 (46.4)Increased ALP10 (35.7)Vomiting6 (21.4)Pale5 (17.8)AnemiaIncreased serum bilirubin3 (10.7)2 (7.1)Weakness2 (7.1)Weight loss2 (7.1)Increased ALT1 (3.6)Epigastric pain1 (3.6)Hepatic encephalopathy1 (3.6)Tiredness1 (3.6)High + High (4)Fever4 (100)Increased ALP2 (50)Anorexia1 (25)Epigastric pain1 (25)Increased ALT1 (25)Increased serum bilirubin1 (25)Aspirin -- Ramipril (28)Low + Low (21)Increased BUN18 (85.7)Monitor patients' blood pressure, hemodynamic parameters, and renal function. Incase of an adverse event, consider the following: (a) replace ACE inhibitors with angiotensin receptor blockers (b) an alternative non-aspirin antiplatelet agent (c) aspirin dosage less than 100 mg per day.Increased serum creatinine12 (57.1)Hypertension9 (42.8)Tachycardia8 (38.1)Confused3 (14.3)Hypokalemia3 (14.3)Chest pain2 (9.5)Headache1 (4.7)Irregular heart rate1 (4.7)Low + High (7)Hypertension5 (71.4)Increased BUN3 (42.8)Increased serum creatinine3 (42.8)Tachycardia2 (28.6)Chest pain1 (14.3)Hyperkalemia1 (14.3)Albuterol -- Furosemide (28)High + High (9)Tachycardia4 (44.4)Potassium balance and cardiovascular status should be monitored, especially if the beta-2 agonist is administered by nebulizer or systemically. Patients should be advised to inform their physician if they experience potential signs/symptoms of hypokalemia such as constipation, numbness, myalgia, abdominal pain, fatigue, tingling, weakness, irregular heartbeat, muscle cramps, and palpitation.Constipation4 (44.4)Fever3 (33.3)Hypokalemia3 (33.3)Confusion2 (22.2)Vomiting1 (11.1)Dehydration1 (11.1)High + Low (17)Constipation4 (23.5)Tachycardia4 (23.5)Hypokalemia4 (23.5)Confusion3 (17.6)Vomiting2 (11.7)Fatigue2 (11.7)Weakness2 (11.7)Fever1 (5.9)Low + High (1)Constipation1 (100)Low + Low (1)Constipation1 (100)Aspirin -- Bisoprolol (23)Low + Low (14)Hypertension7 (50)Patients' blood pressure and hemodynamic parameters should be monitored.Tachycardia4 (28.5)Chest pain3 (21.4)Irregular heart rate2 (14.3)Headache2 (14.3)Restless1 (7.1)Drowsiness1 (7.1)Low + High (7)Hypertension6 (85.7)Tachycardia6 (85.7)Chest pain3 (42.8)Irregular heart rate2 (28.6)High + High (1)Irregular heart rate1 (100)Headache1 (100)Hypertension1 (100)Tachycardia1 (100)High + Low (1)----*ALT* Alanine Aminotransferase, *ACE* Angiotensin Converting Enzyme, *ALP* Alkaline Phosphatase, *APTT* Activated Partial Thromboplastin Time, *BUN* Blood Urea Nitrogen, *FBS* Fasting Blood Sugar, *GIT* Gastrointestinal Tract, *HbA1c* Glycated hemoglobin (A1c), *INR* International Normalized Ratio, *LFTs* Liver Function Tests, *PT* Prothrombin Time, *RBS* Random Blood Sugar^a^Frequencies were given in round brackets^b^Adverse outcomes were defined as follows, increased blood urea nitrogen (BUN): BUN ≤20 mg/dL; increased serum creatinine: serum creatinine \> 1.06 mg/dL; hypernatremia: serum sodium \> 145 mmol/L; hyponatremia: serum sodium \< 135 mmol/L; hyperkalemia: serum potassium \> 5.5 mmol/L; hypokalemia: serum potassium \< 3.5 mmol/L; hyperchloremia: serum chloride \> 105 mmol/L; hypertension: systolic blood pressure (BP) \> 130 mmHg and/or diastolic BP \> 90 mmHg; hypotension: systolic BP \< 80 mmHg and/or diastolic BP \< 50 mmHg; tachycardia: heart rate \> 100 beats/min; bradycardia: heart rate \< 70 beats/min; increased activated partial thromboplastin time (APTT): APTT \> 35.5 s; increased prothrombin time (PT): PT \> 15.5 s; increased international normalized ratio (INR): INR \> 1.2; decreased platelets: platelets count \< 150,000/μL; hypoglycemia: random blood sugar \< 80 mg/dL or fasting blood sugar \< 70 mg/dL; increased alkaline phosphatase: \> 126 U/L; increased serum bilirubin: \> 1 mg/dL; increased alanine aminotransferase: \> 59 U/L (male), \> 36 U/L (female); leukocytosis: total leukocyte count \> 11,000/μL^c^Percentages were calculated based on dose categories

Discussion {#Sec16}
==========

The issue of drug interactions remains one of the considerable factors among hospitalized patients \[[@CR7]\]. This report presents the prevalence, categorization, risk factors, and clinical relevance of pDDIs among hospitalized pneumonia patients. The area remains poorly addressed, locally as well as globally, therefore such studies are needed. The overall prevalence of pDDIs in the current study was higher (73.1%) as compared with that among patients with certain diseases such as HIV (52.2%) \[[@CR22]\], liver cirrhosis (21.5%) \[[@CR23]\], hypertension (48%) \[[@CR24]\], and pediatric patients with respiratory diseases (38.9%) \[[@CR25]\]. While, this prevalence of pDDIs is lower in comparison with that among patients with chronic obstructive pulmonary disease (90%) \[[@CR26]\] and hemodialysis (89.1%) \[[@CR27]\]. Moreover, in our sample, prevalence of major-pDDIs was higher (53.8%) in comparison to that among patients with chronic obstructive pulmonary disease (20% at hospital admission and 24% at hospital discharge) \[[@CR26]\], liver cirrhosis (21.4%) \[[@CR23]\], hepatitis C (30--44%) \[[@CR28]\], and pediatric patients with respiratory diseases (9.5%) \[[@CR25]\]. Regardless of variations in the study design, study population, drug utilization/prescribing pattern, consideration of pDDIs types, and drug interaction screening software, our findings indicated higher prevalence of pDDIs. Based on the current findings, patients with pneumonia are at higher risk to DDIs. Therefore, to minimize, prevent, or manage DDIs in hospitals settings following evidence-based strategies have been suggested: use of computerized screening programs for screening medications profiles for pDDIs \[[@CR29]\], involving clinical pharmacist for the assessment of pDDIs \[[@CR11], [@CR13], [@CR30]\], method for structured evaluation of pDDIs \[[@CR31]\], and appraisal of pertinent labs investigations for clinical relevance of interactions \[[@CR7], [@CR32]\].

Identifying the type of pDDIs by health care professionals is necessary for the management of adverse events related to pDDIs, reducing/preventing the associated risk, and clinical management of pDDIs. In this study, pDDIs of moderate- and major-severity were frequently identified. Concerning documentation-levels, fair- and good-type were highly prevalent. Similar findings were observed by other studies among hospitalized patients \[[@CR14], [@CR15], [@CR24]\]. These findings warrant pneumonia patients to be at risk for the pDDIs associated adverse consequences. Such patients should be monitored for any negative clinical consequences expected due to DDIs.

Polypharmacy is a considerable issue in hospitalized patients with pneumonia \[[@CR5]\]. It refers to prescribing more than five drugs at a time \[[@CR33], [@CR34]\]. Pneumonia patients receive co-prescription of a number of medicines for the treatment of comorbidities or associated symptoms \[[@CR5], [@CR6]\]. A positive relationship of polypharmacy with pDDIs reported by our study is supported by previous published studies \[[@CR12], [@CR14], [@CR35], [@CR36]\]. Moreover, in this study separate odds of exposure to major-pDDIs have been calculated. The findings of statistically significant relationship of major-pDDIs with polypharmacy are consistent with findings from previous studies \[[@CR36], [@CR37]\]. In addition, we found significant association of major-pDDIs with tuberculosis. The possible reason is prescription of anti-TB drugs among patients with TB and these drugs are responsible for a large number of clinically important DDIs \[[@CR38]\]. In this regard, hospitalized patients with pneumonia are at increased risk to pDDIs due to these predictors. Health care professionals should have knowledge regarding all predictors increasing the risk of pDDIs to individualize patients more at risk, optimize medications therapy, and minimize or prevent pDDIs.

PDDIs of any type of severity are not clinically important. So, developing list of clinically important and most frequently observed interactions is of immense need. The list will be used by physicians and pharmacists for the development of therapeutic guidelines and timely/selective identification of pDDIs. A physician's understanding and knowledge of DDIs can reduce the occurrence of associated adverse events, adjust therapeutic regimen of high-risk patients, provide better quality care, and prevent associated medico-legal concerns. In this study, potential adverse consequences of the most frequent pDDIs were nephrotoxicity, hypokalemia, bleeding, hypoglycemia, hepatotoxicity, reduction in therapeutic effectiveness, hypotension, QT interval prolongation, and hyperkalemia. These findings are somehow consistent with findings of a study on hospitalized patients with liver cirrhosis in which most prevalent potential adverse outcomes due to pDDIs were hyperkalemia, hypoglycemia, renal function deterioration, QT interval prolongation, and bleeding risk \[[@CR23]\].

We have related potential adverse effects of DDIs with clinical manifestations of the patients. Such analysis is rarely observed in published literature. Some studies have investigated adverse effects related to interactions but these studies do not specify monitoring parameters and adverse effects for most commonly interacting drug pairs \[[@CR23], [@CR39]\]. This is a novel approach that will be helpful for health care professionals to monitor and manage the adverse outcomes related to interactions. This study also considered doses of the administered drugs. Higher doses of the drugs may potentiate the negative consequences of the interactions. As evident from our findings that adverse events were more prevalent among patients prescribed with higher doses as compared to lower doses. Such considerations give more insight in understanding and management of adverse outcomes of interactions. Furthermore, monitoring parameters and management guidelines will support health care professionals regarding proper assessment and management of drug interactions in pneumonia.

Strengths and limitations {#Sec17}
-------------------------

Following are the potential limitations of this study. The pDDIs recorded in this report are mainly associated with the use of medicines for managing several comorbid illnesses or associated signs/symptoms because of hospitalization of pneumonia patients due to these conditions. Therefore, the findings of this study might not be applicable to ambulatory patients because of variable nature/prevalence of disease and drug interactions. Furthermore, we use the term potential DDIs, as, we do not actually observe DDIs. Data are scarce, concerning negative clinical consequences caused by DDIs, but, some retrospective studies are available in the published literature. One study observed increased odds ratios for digoxin toxicity among patients treated with clarithromycin, for hypoglycemia in patients with co-trimoxazole combined with glyburide, and for hyperkalemia among patients who used ACE inhibitors and potassium-sparing diuretics, concurrently \[[@CR8]\]. Another study, reported that, there is five times increase risk of sudden death due to cardiac causes, among patients who were treated with erythromycin and CYP3A inhibitors, concurrently \[[@CR40]\].

Conclusions {#Sec18}
===========

PDDIs are highly prevalent in patients with pneumonia. Computerized drug interactions screening programs will help in identification, prevention, and minimization of pDDIs in pneumonia patients. Most frequent and clinically important pDDIs need particular attention. Polypharmacy and tuberculosis increase the risk of pDDIs. Identifying patients more at risk to pDDIs and careful monitoring of pertinent signs/symptoms and laboratory investigations are important measures to reduce pDDIs and their related adverse consequences.

ACE

:   Angiotensin converting enzyme

ADRs

:   Adverse drug reactions

ALP

:   Alkaline phosphatase

ALT

:   Alanine aminotransferase

APTT

:   Activated partial thromboplastin time

ATD

:   Alternate day

BD

:   Twice a day

BP

:   Blood pressure

BUN

:   Blood urea nitrogen

CI

:   Confidence interval

DDIs

:   Drug-drug interactions

FBS

:   Fasting blood sugar

GIT

:   Gastrointestinal tract

HbA1c

:   Glycated hemoglobin (A1c)

HMC

:   Hayatabad medical complex

INR

:   International normalized ratio

IQR

:   Interquartile range

KTH

:   Khyber teaching hospital

LFTs

:   Liver function tests

OD

:   Once a day

OR

:   Odds ratios

pDDIs

:   potential DDIs

PT

:   Prothrombin time

QID

:   Four times a day

RBS

:   Random blood sugar

TDS

:   Three times a day
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